Gonadotrophin-releasing hormone (GnRH) analogue Goserelin, Buserelin
- ATC Code
- Indications and NEMLC Recommendations 1
- Indications and NEMLC Recommendations 2
- Indications and NEMLC Recommendations 3
ATC CODE
- L02AE03
INDICATIONS AND NEMLC RECOMMENDATIONS
INDICATIONS AND NEMLC RECOMMENDATIONS 1
INDICATION
- Endometriosis.
NEMLC RECOMMENDATION
- Approved - for use in the following situations:
- For endometriosis-associated infertility prior to in vitro fertilisation (IVF) .
For medical management in situations in which a trial of adequate analgesia or the use of combined oral contraceptives is unsuccessful.
REVIEW INDICATORS
- New evidence based on Goserelin vs. Placebo.
- Large comparative trials with COCs for both "trial of hormone therapy" and for relief of pain.
- Comparisons with new agents such as aromatase inhibitors.
DATE RATIFIED
- 13 March 2008
INDICATIONS AND NEMLC RECOMMENDATIONS 2
INDICATION
- Precocious puberty.
NEMLC RECOMMENDATION
- Approved - Choice of GnRH analogue will depend on best tender price.
REVIEW INDICATORS
- Change in price or registration of new agents which are cheaper or more efficacious, or both. New safety concerns.
DATE RATIFIED
- 13 March 2008
INDICATIONS AND NEMLC RECOMMENDATIONS 3
INDICATION
- As bridging therapy until orchiectomy.
NEMLC RECOMMENDATION
- Approved - Only Approved as bridging therapy - not long-term management.
REVIEW INDICATORS
- Price
DATE RATIFIED
- 25 February 2016